Real-world study in infants fed with an infant formula with two human milk oligosaccharides

Estudio en condiciones reales de lactantes alimentados con una fórmula infantil con dos oligosacáridos de leche humana

Enriqueta Román Riechmann, José Manuel Moreno Villares, Francisco Domínguez Ortega, Alfonso Carmona Martínez, Leandro Picó Sirvent, Luz Santana Sandoval, José Casas Rivero, Ayham Alshweki, Colin Ceracmondi, Samir Dahbane and María Luisa Vidal-Guevara

Gastroenterology and Nutrition Unit. Pediatrics Department. Hospital Universitario Puerta de Hierro Majadahonda. Majadahonda, Madrid, Spain. 2Pediatrics Department. Clínica Universidad de Navarra. Pamplona, Spain. 3Pediatrics and Neonatology Unit. Pediatrics Department. Hospital Vitha Santa Catalina. Las Palmas, Spain. 4Pediatrics Department. Grupo Hispalense de Pediatría. Seville, Spain. 5Pediatrics Department. Hospital Casa de la Salud. Valencia, Spain. 6Pediatrics Department. Hospital Universitario Quirón-Dexeus. Barcelona, Spain. 7Pediatrics Department. Hospital Rúber Internacional. Madrid, Spain. 8Pediatrics Department. Hospital Maternal MH Belén. A Coruña, Spain. 9Nestlé Product Technology Center. Nestlé Nutrition. Vevey, Switzerland. 10Global Medical Affairs. Nestlé Nutrition. Vevey, Switzerland. 11Medical & Scientific Affairs. Nutrición Infantil. Nestlé. Barcelona, Spain

Abstract

Introduction: human milk oligosaccharides (HMOs) are an important component of human milk supporting the development of a balanced intestinal microbiota and immune functions in breastfed infants. Randomized controlled trials (RCTs) have demonstrated that infant formulas supplemented with the HMOs 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT) are safe, well-tolerated, and support normal growth. This Real-World Evidence (RWE) study aimed to evaluate growth and tolerance in infants consuming a formula supplemented with 1 g/L of 2′FL and 0.5 g/L of LNnT, and included a mixed-feeding group never studied before in RCTs.

Participants and methods: this open-label, prospective study was conducted at six centers in Spain, and included healthy, exclusively breastfed infants (BF group), an exclusively formula-fed group (FF) who received a milk-based formula with 2′FL and LNnT, and a group mixed fed with both formula and human milk (MF), for 8 weeks. Co-primary outcomes were growth (anthropometry) and gastrointestinal tolerance (Infant Gastrointestinal Symptom Questionnaire, IGSQ). Secondary outcomes included formula satisfaction and adverse events (AEs).

Results: 159 infants completed the study (66 FF, 48 MF, and 45 BF). Mean z-scores for growth were similar between all groups and within ± 0.5 of WHO medians at week 8. Composite IGSQ scores demonstrated low GI distress in all groups, with no significant group differences at baseline, week 4, or week 8. Incidence of AEs was low overall, and comparable across groups.

Conclusions: in this RWE study examining a HMO-supplemented infant formula, growth and tolerance outcomes were similar to RCT findings, supporting the effectiveness of this early feeding option.

Received: 16/03/2020 • Accepted: 11/06/2020

Funding source: Nestlé España, S.A. Prior presentations: abstract accepted for oral communication to a Symposium at the Annual Meeting of the Spanish Society of Research in Pediatric Nutrition and Feeding (October 2019, Madrid, Spain).

Authors contribution: In the conception and design, and the acquisition or analysis and interpretation of data: AA, ACM, CC, ERR, JCR, JMMV, FDE, LPS, LSS, MVG, and SD. In the writing of the manuscript and the critical review of the intellectual content: CC, ERR, JMMV, MLVG, and SD. In the approval of the final version: AA, ACM, ERR, JCR, JMMV, FDE, LPS, and LSS.

Conflicts of Interest: ERR, and JMMV received honoraria for their consultancy services, and also received speaker grants from Nestlé Nutrition (Spain). AA, ACM, ERR, JCR, JMMV, FDE, LPS and LSS, and their clinical centers, received honoraria from Nestlé Nutrition (Spain) as study investigators. CC, MLVG and SD are current Nestlé employees.

Acknowledgments: The authors thank the families who consented to their infants’ participation in this study, as well as the investigators’ study teams for their major contributions to this study. The authors also thank Xavier Bona for his editorial assistance funded by Nestlé Nutrition, Jian Yan, Nestlé Product Technology Center, for his assistance in study design, and Luca Lavalie and Dominik Grathwohl, Nestlé Research Center, for their statistical analysis.

Correspondence:
Enriqueta Román Riechmann. Gastroenterology and Nutrition Unit. Pediatrics Department. Hospital Universitario Puerta de Hierro Majadahonda. C/ Manuel de Falla, 1. 28222 Majadahonda, Madrid. Spain. e-mail: enriqueta.roman@salud.madrid.org

©Copyright 2020 SENPE y ©Arán Ediciones S.L. Este es un artículo Open Access bajo la licencia CC BY-NC-SA (http://creativecommons.org/licenses/by-nc-sa/4.0/).
INTRODUCTION

Human milk oligosaccharides (HMOs) are found in abundance in human milk and make up the largest solid component after lactose and lipids (1-4). Bovine milk, in contrast to human milk, contains relatively low levels of oligosaccharides, and the prevalence of fucosylated oligosaccharides, in particular, is quite low (5). 2′fucosyllactose (2′FL) is a trisaccharide composed of glucose, galactose, and fucose, and is one of the most abundant HMOs. Levels of 2′FL vary depending on the secretor blood group status of an individual woman as well as on ethnicity and stage of lactation, with 2′FL levels from about 0.9 to above 4 gram/liter (g/L) in mature milk among secretors (6-14). Another HMO in human milk is lacto-N-neotetraose (LNnT), in levels ranging from 0.1 to 0.6 g/L, with higher levels within the first month of lactation (7-10,15-17).

Evidence is emerging that HMOs play an important role in the development of a balanced intestinal microbiota and in supporting immune protection in breastfed infants (18-20). Preclinical models have found that both 2′FL and LNnT promote the growth of *Bifidobacterium* species (21,22). Additionally, in a randomized controlled trial (RCT) of a term infant formula supplemented with 2′FL and LNnT, lower rates of parent-reported morbidity (particularly lower respiratory tract illnesses such as bronchitis) and lower use of antibiotics in the group receiving HMO-supplemented formula were reported as compared to the control fed infants (23). In a subset of the infants in this same RCT, stool samples collected for microbiota assessment and metabolic signature at three months showed that the addition of 2′FL and LNnT shifted the stool microbiota closer to that observed in breastfed infants both in composition and function (24). Collectively, these findings, in conjunction with the documented differences in HMO composition between human and bovine milk, have provided a solid rationale for supplementing bovine milk-based infant formulas with HMOs.

Advancements in manufacturing technology now enable the synthesis of HMOs, and preclinical studies have established their safety for the purposes of supplementation of infant formulas (25,26). Safety, tolerance, and adequate growth, as well as potential clinical benefits, have been demonstrated in RCTs of term infant formulas supplemented with 2′FL alone and in combination with LNnT (23,27,28). The first such report was an RCT of growth and tolerance conducted in the US, which found that infants receiving a formula supplemented with either galacto-oligosaccharides [GOS] or GOS + 2′FL demonstrated adequate growth and good tolerance (27). A second RCT conducted in Belgium and Italy examined a study formula containing 1.0 g/L of 2′FL and 0.5 g/L of LNnT in the test arms, while the control arm received a standard formula without HMOs (23). The HMO-supplemented formula was again well-tolerated and supported age-appropriate growth. A third study in the US compared tolerance in infants receiving a 100 % whey, partially hydrolyzed infant formula with the probiotic *B. lactis*, with and without the further addition of 2′FL, and found that the HMO-supplemented formula was well tolerated (28).

While the evidence provided to date in RCTs is supportive of the safety and tolerance of HMO-supplemented infant formulas, studies are needed in a real-world setting because results from a highly controlled RCT do not always translate outside of the trial setting (29). Additionally, a relatively large proportion of infants in real-world settings are fed both human milk and formula (30-32), a mixed feeding regimen not studied in previous RCTs. The current study was thus designed to complement and enhance existing RCTs by assessing the growth, safety and tolerance of healthy term infants consuming an infant formula supplemented with HMOs either exclusively or mixed with human milk in a real-world setting.

PARTICIPANTS AND METHODS

STUDY DESIGN

This was a three-group, non-randomized, open-label, prospective study in healthy, term (37-42 weeks of gestation) infants enrolled at age 7 days to 2 months. The study was conducted between October 2018 and March 2019 in six centres throughout...
STUDY PRODUCT

The study formula was provided to the participants. Commercially available in Spain since 2017, it was a partially hydrolyzed, 100 % whey, term infant reconstituted formula with 67 kcal/100 mL consisting of 1.9 g of protein, 11.5 g of carbohydrates, and 5.1 g of lipids per 100 kcal powder, and with two HMOs: 1.0 g/L of 2’FL and 0.5 g/L of LNnT. The formula also included *Lactobacillus reuteri* (DSM 17938), vitamins and minerals.

ETHICAL APPROVAL AND INFORMED CONSENT

This study protocol was approved by the coordinating Hospital Institutional Review Board of Puerta de Hierro, Majadahonda (Madrid). Prior to the conduct of any screening tests, an informed consent was obtained from each participant’s parent. Good clinical practice was followed by all sites throughout the study. The study was registered with ClinicalTrials.gov (NCT04055363).

STUDY MEASURES

At baseline, anthropometry measures were obtained including weight, length, and head circumference using standardized procedures. Anthropometric parameters were measured again during the clinic visit at week 8. BMI was calculated as weight (kg)/length (m)^2_. Z-scores for weight-for-age, length-for-age, head circumference-for-age, and BMI-for-age were calculated using the WHO Child Growth Standards (33).

The infant’s gastrointestinal (GI) symptom burden was assessed via the Infant Gastrointestinal Symptom Questionnaire (IGSQ), a validated 13-item questionnaire that assesses GI-related signs and symptoms as observed by parents over the previous week in 5 domains: stooling, spitting up/vomiting, gassiness, crying, and fussing. Each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress (34). The IGSQ was administered at baseline, week 4, and week 8.

A formula satisfaction questionnaire was administered to parents of infants in the formula-fed groups at week 4 and week 8 including three questions regarding the parents’ experience with the study formula. Questions included ‘Did your child like what he/she consumed?’ , ‘How satisfied are you overall with the study product?’ , and ‘Would you continue to provide the study formula to your child?’

Adverse Events (AE) were captured from the time of enrollment through the end of study. All AEs were assessed by the site investigator for duration, intensity, frequency, and relationship to study formula. AEs were classified into System, Organ, and Class (MedDRA SOC codes).

STATISTICAL METHODS

Demographics and other baseline characteristics were compared for overall differences between the feeding groups using the Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorial variables. Pairwise comparisons were done using two-sided Wilcoxon’s rank-sum tests (continuous variables) and two-sided Fisher’s exact tests (categorial variables) adjusted for multiplicity by the Holm procedure. Fisher’s exact tests were computed from contingency tables. For tables larger than 2 x 2 a Monte Carlo estimation of the exact p-value was performed with 20,000 samples, otherwise a direct exact p-value computation was performed. Missing values were excluded before performing the aforementioned tests.

The co-primary outcomes were growth and composite IGSQ score. Feeding group comparisons were assessed for all growth measures using the analysis of covariance (ANCOVA) with adjustment for baseline value, age, gender, and study center. Tolerance was assessed via the IGSQ scores. The 13 individual questions in the IGSQ, as well as the five domain scores, were tabulated for each feeding group at each time point. The composite IGSQ scores were calculated for each feeding group and compared between feeding groups using ANCOVA with adjustment for baseline IGSQ score.

All analyses were conducted using the SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA). Statistical significance was assessed using an α level of 5 % with a two-sided test.
REAL-WORLD STUDY IN INFANTS FED WITH AN INFANT FORMULA WITH TWO HUMAN MILK OLIGOSACCHARIDES

Being a RWE study, sample size was determined based on previous RCTs, aiming to have an analysis set of at least 40-50 subjects per group. Infants who were not compliant with the study protocol were withdrawn from the study and did not continue to participate in the study measurements or visits. The analysis set was defined by excluding infants who did not have a growth and/or tolerance measurement at week 8. All analyses of growth, tolerance, and satisfaction in this paper were conducted in the analysis set. Adverse events were reported for all enrolled infants.

RESULTS

SUBJECT DISPOSITION AND DEMOGRAPHICS

In this study, 207 infants were enrolled including 82 exclusively formula-fed (FF), 62 mixed-fed (MF), and 63 exclusively breastfed (BF) infants (Fig. 1). The number of subjects in the analysis set (those with tolerance and growth measurements at the end of 8 weeks of study) were 66, 48, and 45, respectively, in the FF, MF, and BF groups, with primary exclusion reasons being major protocol deviations and losses to follow-up.

The demographics and baseline characteristics of all enrolled infants are shown in table I. The FF group was slightly younger at enrollment as compared with the MF group and BF group (p < 0.01), with more male infants in contrast to the MF or BF groups. Gender distribution was, however, not statistically different between groups (p > 0.05). Other baseline characteristics were also comparable across the feeding groups, including age, educational attainment, and smoking status of the mothers and fathers. The baseline characteristics of the analysis set (n = 159) were similar to those of all enrolled infants for all feeding groups (data not shown).

GROWTH

Overall, age-appropriate growth was observed in all three feeding groups. Baseline weight and length were slightly lower in the FF group (FF mean weight of 3.34 kg versus 3.75 and 3.93 in the MF and BF groups, respectively; FF mean length of 50.62 cm versus 51.86 and 52.82 cm in the MF and BF groups, respectively), which is consistent with the slightly younger age. By Week 8, there were no significant differences between any feeding groups for any of the anthropometric measures (all ANCOVA p-values between feeding groups > 0.05). Mean Z-scores for weight, length, head circumference, and BMI at baseline and week 8 are shown in figure 2. Weight-for-age, length-for-age, and BMI-for-age z-scores were similar between all feeding groups, and the mean z-scores were within ± 0.5 of the WHO medians at week 8. Head circumference-for-age z-scores were also similar between groups and tracked closely with the WHO standards.

GASTROINTESTINAL TOLERANCE

Table II shows descriptive characteristics for the five IGSQ domains and the overall composite score. Composite IGSQ scores demonstrated low GI distress in all feeding groups at all time

Figure 1.
Flow chart of subject disposition.
points, and there were no significant differences between feeding groups at baseline, week 4, or week 8. Within each feeding group, for four of the five domains of the IGSQ (gassiness, fussiness, crying, and spitting-up/vomiting) there were no significant differences in scores between baseline and week 4 or week 8 (data not shown). For the fifth domain, stooling, FF infants had scores significantly different from the ones in the BF group ($p < 0.001$) at baseline, and showed significant improvement at week 8 (mean change $[95 \% \text{ confidence interval}] = -0.79 [-1.35, -0.23]$, $p < 0.01$), moving closer to the stooling profile of the BF group. The scores for stooling of MF infants were significantly different from those of the BF infants at baseline ($p < 0.05$) and week 8 ($p < 0.05$).

**Table I. Demographics and baseline characteristics (shown as N and % unless otherwise noted), by feeding group, all enrolled subjects (n = 207)**

| Subject characteristics | BF (n = 63) | MF (n = 62) | FF (n = 82) | p-value$^1$ |
|-------------------------|------------|------------|------------|------------|
| Age at enrollment, days (median [IQR]) | 13 (9-32) | 13.5 (10-33) | 10 (8-15) | $< 0.01^2$ |
| Gender                   |            |            |            | 0.50       |
| Male                     | 28 (44.4 %) | 27 (43.6 %) | 43 (52.4 %) |            |
| Female                   | 35 (55.6 %) | 35 (56.5 %) | 39 (47.6 %) |            |
| Ethnicity                |            |            |            | 0.84       |
| Black                    | 2 (3.2 %)  | 2 (3.2 %)  | 1 (1.2 %)  |            |
| Caucasian                | 59 (93.7 %)| 58 (93.6 %)| 79 (96.3 %)|            |
| Other                    | 2 (3.2 %)  | 2 (3.2 %)  | 2 (2.4 %)  |            |
| Days breastfed since birth (median [IQR]) | 13 (9-32) | 13 (10-32) | 0 (0-0) | $< 0.01^1$ |
| Days formula-fed since birth (median [IQR]) | 0 (0-0) | 12 (7-22) | 10 (8-15) | $< 0.01^1$ |
| Mother’s age, years (median [IQR]) | 35 (31-36) | 35 (32-38) | 35 (32-38) | 0.27       |
| Mother’s highest level of education |            |            |            | 0.69       |
| Primary school           | 2 (3.2 %)  | 0 (0.0 %)  | 3 (3.7 %)  |            |
| High school              | 6 (9.5 %)  | 9 (14.5 %) | 13 (15.9 %)|            |
| College or above         | 40 (63.5 %)| 39 (62.9 %)| 45 (54.9 %)|            |
| Professional school      | 15 (23.8 %)| 14 (22.6 %)| 21 (25.6 %)|            |
| Mother smoked during pregnancy | 4 (6.4 %) | 1 (1.6 %)  | 7 (8.5 %)  | 0.22       |
| Father’s years, days (median [IQR]) | 37 (33-40) | 37 (33-40) | 37 (33-39) | 0.75       |
| Father’s highest level of education |            |            |            | 0.54       |
| Primary school           | 1 (1.6 %)  | 3 (4.8 %)  | 10 (12.2 %)|            |
| High school              | 8 (12.7 %) | 8 (12.9 %) | 14 (17.1 %)|            |
| College or above         | 32 (50.8 %)| 30 (48.4 %)| 28 (34.2 %)|            |
| Professional school      | 18 (28.6 %)| 17 (27.4 %)| 19 (23.2 %)|            |
| Missing or less than primary school | 4 (6.4 %) | 4 (6.5 %)  | 11 (13.4 %)|            |
| Father is a smoker       | 15 (23.81 %)| 13 (20.97 %)| 17 (20.73 %)| 0.97       |

BF: exclusively breastfed; MF: mixed fed; FF: formula fed (exclusively); IQR: interquartile range (Q1-Q3); SD: standard deviation. $^1$Global p-values to detect any difference between the three feeding groups using the Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorical variables. $^2$FF different from MF and BF ($< 0.01$) using two-sided Wilcoxon rank-sum tests adjusted for multiplicity by the Holm procedure. $^3$BF different from MF and FF ($< 0.01$) using two-sided Wilcoxon rank-sum tests adjusted for multiplicity by the Holm procedure.

**FORMULA SATISFACTION**

Formula satisfaction is summarized in table III. Nearly all parents reported satisfaction with the study product. More than 90 % of parents also reported at both week 4 and week 8 that their child liked what he/she consumed and that they would continue to provide the study formula to their child.

**ADVERSE EVENTS**

A total of 49 subjects experienced 58 adverse events (AEs) during the course of the study, including 18 AEs in the BF group,
Table II. Descriptive statistics for IGSQ domains, and composite scores at baseline, week 4, and week 8, by feeding group, analysis set (n = 159)

|                      | BF               | MF               | FF               |
|----------------------|------------------|------------------|------------------|
|                      | n    | Mean | SD   | Min-Max | n    | Mean | SD   | Min-Max | p-value* | n    | Mean | SD   | Min-Max | p-value* |
| IGSQ domains         |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Stooling             |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 41   | 2.32 | 0.82 | 2-6     | 45   | 2.93 | 1.21 | 2-6     | 0.045    | 62   | 3.47 | 1.80 | 2-9     | < 0.001  |
| Week 4               | 45   | 2.24 | 0.65 | 2-5     | 48   | 2.83 | 1.55 | 2-8     | 0.18     | 65   | 3.29 | 2.11 | 2-10    | 0.012    |
| Week 8               | 45   | 2.18 | 0.39 | 2-3     | 48   | 2.85 | 1.52 | 2-8     | 0.025    | 66   | 2.71 | 1.26 | 2-7     | 0.07     |
| Spitting-up / Vomiting|      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 38   | 6.26 | 2.83 | 4-16    | 41   | 5.88 | 1.83 | 4-11    | 0.49     | 60   | 6.17 | 2.62 | 4-15    | 0.85     |
| Week 4               | 41   | 6.00 | 2.27 | 4-13    | 47   | 5.62 | 1.76 | 4-11    | 0.35     | 62   | 5.76 | 2.32 | 4-15    | 0.38     |
| Week 8               | 45   | 5.62 | 1.83 | 4-10    | 45   | 5.56 | 2.18 | 4-12    | 0.93     | 65   | 5.88 | 2.08 | 4-11    | 0.53     |
| Crying               |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 39   | 4.08 | 1.69 | 3-11    | 43   | 4.56 | 2.25 | 3-14    | 0.35     | 61   | 4.79 | 2.65 | 3-15    | 0.13     |
| Week 4               | 44   | 4.00 | 1.48 | 3-9     | 46   | 4.17 | 1.95 | 3-12    | 0.77     | 66   | 4.58 | 2.19 | 3-12    | 0.18     |
| Week 8               | 44   | 3.89 | 1.37 | 3-8     | 47   | 4.04 | 1.61 | 3-10    | 0.98     | 64   | 4.30 | 1.76 | 3-11    | 0.38     |
| Fussiness            |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 41   | 4.00 | 2.07 | 2-10    | 39   | 4.00 | 2.10 | 2-10    | > 0.99   | 59   | 3.83 | 2.16 | 2-10    | 0.69     |
| Week 4               | 44   | 3.52 | 2.25 | 2-10    | 43   | 3.77 | 2.27 | 2-9     | 0.75     | 58   | 4.10 | 2.28 | 2-10    | 0.24     |
| Week 8               | 42   | 3.31 | 1.88 | 2-8     | 35   | 3.63 | 2.31 | 2-10    | 0.68     | 61   | 3.48 | 1.82 | 2-10    | 0.7      |
| Gassiness            |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 41   | 5.17 | 2.07 | 2-9     | 44   | 5.20 | 2.09 | 2-10    | 0.94     | 63   | 4.92 | 2.27 | 2-10    | 0.57     |
| Week 4               | 45   | 4.69 | 1.77 | 2-8     | 48   | 4.94 | 2.00 | 2-9     | 0.67     | 65   | 5.09 | 2.40 | 2-10    | 0.21     |
| Week 8               | 45   | 4.82 | 1.77 | 2-8     | 48   | 4.38 | 2.05 | 2-10    | 0.11     | 66   | 4.30 | 1.98 | 2-10    | 0.12     |
| COMPOSITE IGSQ SCORE |      |      |      |         |      |      |      |         |          |      |      |      |         |          |
| Baseline             | 41   | 21.95| 6.38 | 13-37   | 45   | 22.43| 6.22 | 13-38   | 0.77     | 63   | 23.26| 8.83 | 13-57   | 0.39     |
| Week 4               | 45   | 20.62| 5.57 | 13-33   | 48   | 21.32| 6.05 | 13-40   | 0.79     | 66   | 22.69| 7.4  | 13-40   | 0.17     |
| Week 8               | 45   | 19.85| 4.74 | 13-30   | 48   | 20.35| 6.50 | 13-40   | 0.97     | 66   | 20.66| 5.76 | 13-36   | 0.63     |

*p-value as compared to breastfed group; BF: exclusively breastfed; MF: mixed fed; FF: formula fed (exclusively); SD: standard deviation.

Figure 2.
Anthropometric mean z-scores at baseline and at week 8, by feeding group, analysis set (n = 159). Bars represent 95 % confident intervals (two-sided).
21 in the MF group, and 19 in the FF group. Three patients experienced potentially product-related AEs, including two instances of cow’s milk intolerance, one in the FF group and one in the MF group, and one instance of irritability in the FF group. Six serious adverse events occurred (4 in the FF group and 2 in the MF group), all of which were bronchiolitis, and all were considered unrelated to the study feeding. The incidence of AEs was low overall and was not significantly different in the three feeding groups.

**DISCUSSION**

This is the first RWE in infants fed a formula supplemented with the HMOs 2’FL and LNnT, and containing *L. reuteri*, in which a breastfed and a mixed-fed group are included. The results demonstrate that formula-fed infants, either exclusively or mixed fed, receiving the HMO-supplemented formula had age-appropriate growth in line with the WHO standards, and that growth was also comparable to that seen in previous studies with west and south European infant populations (35). The formula was well tolerated, as indicated by low IGSQ scores, and GI tolerance in the formula-fed infants was comparable to that in breastfed infants. There was also a low incidence of adverse events in all groups, and despite of the season of the year (fall-winter), cases of bronchiolitis were lower than expected from the literature (36). Finally, parents provided high satisfaction ratings for the HMO-supplemented formula.

The results of this RWE study are similar to those from previous RCTs that have also examined term infant formulas supplemented with HMOs. One RCT was a multicenter, double-blind trial that enrolled 175 healthy term infants in Italy and Belgium at less than 14 days of age, who were fed a study formula for 6 months (23). The HMO-supplemented formula demonstrated age-appropriate growth as well as good tolerance as measured by parents. Another RCT included 189 term infants in the US who were randomized to 1 of 3 different formula groups (27). Infants were exclusively formula fed until 4 months of age. All formulas were considered well tolerated based on parental reports, and no significant differences were observed for growth between groups. Notably, neither of those trials utilized a validated tool to assess tolerance, and thus tolerance outcomes cannot be easily compared across studies. A recent RCT used the same validated IGSQ tool as in the current study to assess tolerance (28). The HMO-supplemented formula was well tolerated as evidenced by similar IGSQ scores between the groups with and without the addition of 2’FL. The agreements between the previous RCTs and the current study in a real-world setting, however, are reassuring that growth, safety and tolerance of the HMO-supplemented formula are consistent and robust across study designs.

This study included several strengths. First, GI burden was measured using a validated instrument, the 13-item IGSQ based on five separate domains of feeding tolerance. The use of a validated instrument provides information that is interpretable by and meaningful to practicing clinicians. Second, this was a RWE study, a design distinct from an RCT, simpler, less restrictive, and in line

| Table III. Formula satisfaction questionnaire results at weeks 4 and 8 among parents of infants receiving the study formula, by feeding group, analysis set (n = 114 infants receiving formula) |
|---|---|---|---|---|
| MF (n = 48) | FF (n = 66) | MF (n = 48) | FF (n = 66) |
| **Week 4** | **Week 8** | **Week 4** | **Week 8** |
| **How satisfied are you overall with the study formula?** | | | |
| Satisfied | 44 (92 %) | 46 (96 %) | 62 (94 %) | 65 (98 %) |
| Neutral | 4 (8 %) | 1 (2 %) | 4 (6 %) | 0 (0 %) |
| Dissatisfied | 0 (0 %) | 0 (0 %) | 0 (0 %) | 0 (0 %) |
| Missing | 0 (0 %) | 1 (2 %) | 0 (0 %) | 1 (2 %) |
| **Would you continue to provide the study formula to your child?** | | | |
| Yes | 47 (98 %) | 45 (94 %) | 66 (100 %) | 63 (95 %) |
| No | 1 (2 %) | 2 (4 %) | 0 (0 %) | 2 (3 %) |
| Missing | 0 (0 %) | 1 (2 %) | 0 (0 %) | 1 (2 %) |
| **Did your child like what he/she consumed?** | | | |
| Yes | 46 (96 %) | 48 (100 %) | 66 (100 %) | 65 (98 %) |
| No | 2 (4 %) | 0 (0 %) | 0 (0 %) | 0 (0 %) |
| Missing | 0 (0 %) | 0 (0 %) | 0 (0 %) | 1 (2 %) |

MF: mixed fed; FF: formula fed (exclusively).
with current clinical practices, enhancing the generalizability of the results and providing additional useful information. The published prevalence of infants who are mixed fed, in Spain (30) and in the US (31) indicate that at age 1 month, 30% of infants receive mixed feeding regimens such as ours, randomization is however not possible. The main aim of randomization is to have study groups with equal characteristics. We therefore compared the baseline characteristics in our three groups and there were no substantial differences except for age, which was lower in the FF as compared to the MF and BF groups. As we corrected all our statistical models with baseline age, we therefore assume that our outcomes are not significantly affected by the slight difference in baseline age between the groups, and hence also not by the non-randomized nature of our trial. The study formula was supplemented with just a single level of 2’FL and LNnT, and thus this study cannot assess whether the observed growth and tolerance effects might differ over a wider range of levels of these HMOs. Additionally, this study, while multi-center, took place within a single country (Spain) and its results may not be generalizable outside of western countries.

In conclusion, this is the first RWE study to examine the effectiveness of supplementing infant formula with HMOs. The results obtained were similar to those found in more tightly controlled RCT settings, indicating robust effects for growth, safety, and tolerance in association with HMO-supplemented infant formulas.

**REFERENCES**

1. Ninonuevo MP, Lebrilla CB. Mass spectrometric methods for analysis of oligosaccharides in human milk. Nutr Rev 2009;67(Suppl 2):S216-26. DOI: 10.1111/j.1753-4887.2009.00243.x

2. Gabrielli D, Zampini L, Galeazzi T, Padella L, Santoro L, Peila C, et al. Preterm milk oligosaccharides during the first month of lactation. Pediatrics 2011;128(6):e1520-31. DOI: 10.1542/peds.2011-1206

3. Zivkovic AM, German JB, Lebrilla CB. Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci U S A 2011;108(Suppl 1):4653-8. DOI: 10.1073/pnas.1000083107

4. Hale TW, Hartmann PE, eds. Textbook of Human Lactation. New York (USA): Springer-Publishing; 2007.

5. Urashima T, Oettel DT. Oligosaccharides in the milk of other mammals. In: McGuire MK, McSweeney MA, Bode L, eds. Prebiotics and Probiotics in Human Milk: Origins and Functions of Milk-Borne Oligosaccharides and Bacteria. McGuire MK, McGuire MA, Bode L, eds. Prebiotics and Probiotics in Human Milk: Origins and Functions of Milk-Borne Oligosaccharides and Bacteria.；2015;91(11):619-22. DOI: 10.1016/j.earlhumdev.2015.09.001

6. Loo F, Asakuma S, Fukuda K, Sendas A, Urashima T. Determination of sialyl and neutral oligosaccharide levels in transition and mature milks of Samoan women, using anthracnose derivatization followed by reverse phase high-performance liquid chromatography. Biosci Biotechnol Biochem 2010;74(2):298-303. DOI: 10.1271/bbb.090614

7. Anakuma S, Urashima T, Akahori M, Obayashi H, Nakamura T, Kinura K, et al. Variation of neutral oligosaccharide levels in human colostrum. Eur J Clin Nutr 2008;62(4):488-94. DOI: 10.1038/sj.ejn.1602738

8. Kulkarni A, Liu L. Human milk oligosaccharides: The role in the fine-tuning of innate immune responses. Carbohydr Res 2016;432-62:70. DOI: 10.1016/j.carres.2016.07.009

9. Lewis ZT, Totten SM, Sliwinski JT, Popovic M, Parker E, Lemay DG, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 2015;3:13. DOI: 10.1186/s40168-015-0071-z

10. Bode L. The functional biology of human milk oligosaccharides. Early Hum Dev 2015;91(11):619-22. DOI: 10.1016/j.earlhuma.2015.09.001

11. Yu ZT, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology 2013;23(11):1281-92. DOI: 10.1093/glycob/cwt065

12. Marcobal A, Barbosa M, Sonnenburg ED, Pudlo N, Martens EC, Dea A, et al. Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe 2011;10(5):507-14. DOI: 10.1016/j.chom.2011.10.007

13. Puccio G, Alliet P, Cagazzo C, Janssens E, Corsello G, Sprenger N, et al. Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. J Pediatr Gastroenterol Nutr 2015;64(4):624-31. DOI: 10.1097/MPG.0000000000001520

14. Alliet P, Puccio, G, Janssens E, Cagazzo C, Corsello G, Berger B, et al. Term infant formula supplemented with human milk oligosaccharides (2′-fucosyllactose and lacto-N-neotetraose) shifts stool microbiota and metabolic signatures closer to that of breastfed infants. J Pediatr Gastroenterol Nutr 2016;63(1S):S55. DOI: 10.1097/01.ndg.0000000000001933

15. Coulet M, Phonthirath P, Aliassilis L, Schiffert B. Pre-clinical safety evaluation of the synthetic human milk, nature-identical, oligosaccharide 2′-O-fucosyllactose (2′FL). Regul Toxicol Pharmacol 2014;68(1):59-69. DOI: 10.1016/j.yrtph.2013.11.005

16. Coulet M, Phonthirath P, Contable A, Marsden E, Schiffert B. Pre-clinical safety evaluation of the synthetic human milk, nature-identical, oligosaccharide Lacto-N-neotetraose (LNnT). Food Chem Toxicol 2013;62:528-37. DOI: 10.1016/j.fct.2013.11.005

17. Marriage BJ, Buck RH, Goehring KC, Oliver JS, Williams JA. Infants Fed a Lower Calorie Formula With 2′FL Show Growth and 2′FL Uptake Like Breast-Fed Infants. J Pediatr Gastroenterol Nutr 2015;61(6):649-58. DOI: 10.1097/MPG.0000000000000889
28. Storm HM, Shepard J, Czerekis LM, Kineman B, Cohen SS, Reichert H, et al. 2’-Fucosyllactose Is Well Tolerated in a 100 % Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial. Glob Pediatr Health 2019;6:2333794X19833995. DOI: 10.1177/2333794X19833995

29. Singal AG, Higgins PD, Wajee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014;5:e45. DOI: 10.1038/ctg.2013.13

30. Cuadrón Andrés L, Samper Villagrasa MP, Álvarez Sauras ML, Lasarte Veilllas JJ, Rodríguez Martínez G, Grupo Colaborativo CALINA. An Pediatr (Barc) 2013;79(5):312-8. DOI: 10.1016/j.anpedi.2013.03.010

31. Karmaus W, Soto-Ramírez N, Zhang H. Infant feeding pattern in the first six months of age in USA: a follow-up study. Int Breastfeed J 2017;12:48. DOI: 10.1186/s13006-017-0139-4

32. Zhang J, Himes JH, Guo Y, Jiang J, Yang L, Lu Q, et al. Birth weight, growth and feeding pattern in early infancy predict overweight/obesity status at two years of age: a birth cohort study of Chinese infants. PLoS One 2013;8(6):e64542. DOI: 10.1371/journal.pone.0064542

33. Group WHOMGRS. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 2006;450:76-85.

34. Riley AW, Trabulsi J, Yao M, Bevans KB, DeRusso PA. Validation of a Parent Report Questionnaire: The Infant Gastrointestinal Symptom Questionnaire. Clin Pediatr (Phila) 2015;54(12):1167-74. DOI: 10.1177/0009922815574075

35. Alexander DD, Yan J, Blysmu L.C, Northington RS, Grathwohl D, Steenhout P, et al. Growth of infants consuming whey-predominant term infant formulas with a protein content of 1.8 g/100 kcal: a multicenter pooled analysis of individual participant data. Am J Clin Nutr 2016;104(4):1083-92. DOI: 10.3945/ajcn.116.130633

36. Meissner HC. Viral Bronchiolitis in Children. N Engl J Med 2016;374:62-72. DOI: 10.1056/NEJMr1413456